ATYR aTYR PHARMA INC
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1339970 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-19.1%
TTM net income YoY-15.8%
TTM EPS YoY7.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-40,856.3%
Net margin-39,009.5%
FCF margin-32,664.7%
EBITDA margin-40,506.8%
Returns
ROE-107.8%
ROA-78.1%
ROIC (approx.)-106.0%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets27.6%
Debt / equity0.00x
Current ratio5.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.84x
Accruals ratio-12.8%
Payout ratio—
Capex / revenue40.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $190,000 | $235,000 |
| R&D expense | $60.22M | $54.37M |
| SG&A expense | $17.60M | $13.78M |
| Operating income | -$77.63M | -$67.91M |
| Pretax income | -$74.12M | -$64.02M |
| Income tax | $0 | $0 |
| Net income | -$74.12M | -$64.02M |
| EBITDA | -$76.96M | -$67.21M |
| EPS (basic) | -0.80 | -0.86 |
| EPS (diluted) | -0.80 | -0.86 |
| Weighted avg. shares (diluted) | 92.99M | 74.26M |
| Balance sheet | ||
| Cash & equivalents | $10.74M | $11.05M |
| Short-term investments | $67.94M | $61.07M |
| Current assets | $80.24M | $81.95M |
| PP&E, net | $4.26M | $4.85M |
| Total assets | $93.00M | $96.83M |
| Current liabilities | $15.15M | $14.97M |
| Total liabilities | $25.71M | $27.00M |
| Shareholders' equity | $67.48M | $70.02M |
| Shares outstanding | 2.45M | 84.04M |
| Cash flow statement | ||
| Operating cash flow | -$61.99M | -$69.12M |
| Capital expenditure | $77,000 | $65,000 |
| Free cash flow | -$62.06M | -$69.18M |
| Investing cash flow | -$5.05M | $17.23M |
| Financing cash flow | $66.01M | $39.86M |
| Depreciation & amortization | $664,000 | $708,000 |
| Stock-based compensation | $5.00M | $2.99M |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.